Combined genetic mutations and DNA-methylated genes as biomarkers for endometrial cancer detection from cervical scrapings

Table 2 Performance of genetic mutations, and methylated gene combinations, in cervical scrapings

Variables	Non-endometrial cancer	Endometrial cancer	P value^a
Number of cases	50	46
Genetic mutation
PTEN			< 0.001
Mutation	7 (14.0%)	24 (52.2%)
Wild type	43 (86.0%)	22 (47.8%)
TP53			< 0.001
Mutation	19 (38.0%)	33 (71.7%)
Wild type	31 (62.0%)	13 (28.3%)
Either mutation			< 0.001
Mutation	29 (58.0%)	42 (91.3%)
Wild type	21 (42.0%)	4 (8.7%)
DNA methylation
BHLHE22+CDO1 (cutoff value > − 0.2)^b			< 0.001
High	6 (12.0%)	39 (84.8%)
Low	44 (88.0%)	7 (15.2%)
BHLHE22+CDO1+HAND2 (cutoff value > 0.22)^b			< 0.001
High	7 (14.0%)	40 (87.0%)
Low	43 (86.0%)	6 (13.0%)
BHLHE22+CDO1+TBX5 (cutoff value > − 0.04)^b			< 0.001
High	10 (20.0%)	41 (89.1%)
Low	40 (80.0%)	5 (10.9%)

^aP values were calculated by the chi-square test
^bCutoff values were calculated by the maximum of Youden’s distance of receiver operating characteristic curve

ISSN: 1868-7083